Skip to main content

Advertisement

SpringerLink
Log in

Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

We investigated changes in quality of life (QOL), including pain, in Japanese women aged ≥ 55 years who were diagnosed as having osteoporosis at 265 centers across Japan and treated continuously with once-weekly bisphosphonates for 24 months. In 2650 evaluable patients, a significant improvement in QOL was observed from 3 months after enrollment onward and maintained throughout the 2-year observation period. A significant improvement in scores was observed for all domains of the Euro QOL 5 Dimension (EQ-5D), and the “pain”, “health perception”, and “posture, figure” domains of the Japanese Osteoporosis QOL Questionnaire (JOQOL). Factors identified as significantly contributing to QOL change were “fractures within the year before enrollment”, “presence of spondylosis deformans”, “presence of osteoarthritis”, “use of activated vitamin D3”, and “age” based on the JOQOL, and “presence of spondylosis deformans”, “use of activated vitamin D3”, and “age” based on the EQ-5D. The results suggested that the patients’ perception of treatment effects, such as improvement in pain, contributes to treatment continuation. Osteoporosis patients should be informed that continuous treatment with once-weekly bisphosphonates can lead to a significant improvement in QOL regardless of concomitant locomotor diseases, to encourage them to remain on treatment. In conclusion, continuous bisphosphonate treatment improved the QOL even in patients with locomotor diseases, and the concomitant use of activated vitamin D3 may also facilitate further improvement in QOL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yoshimura N, Muraki N, Oka H, Kawaguchi H, Nakamura K, Akune T (2010) Cohort profile: research on Osteoarthritis/Osteoporosis Against Disability study. Int J Epidemiol 39:988–995

    Article  PubMed  Google Scholar 

  2. Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27:620–628

    Article  PubMed  Google Scholar 

  3. Committee for the Development of Guidelines for Prevention and Treatment of Osteoporosis (Japan Osteoporosis Society, The Japanese Society for Bone and Mineral Research and Japan Osteoporosis Foundation) (2015) Guidelines for prevention and treatment of osteoporosis (in Japanese). Life Science Publishing Co., Ltd., Tokyo

    Google Scholar 

  4. Kumamoto K, Nakamura T, Suzuki T, Gorai I, Fujinawa O, Ohta H, Shiraki M, Yoh K, Fujiwara S, Endo N, Matsumoto T (2010) Validation of the Japanese Osteoporosis Quality of Life Questionnaire. J Bone Miner Metab 28:1–7

    Article  PubMed  Google Scholar 

  5. Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21

    Article  CAS  PubMed  Google Scholar 

  6. Tsukutani Y, Hagino H, Ito Y, Nagashima H (2015) Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis. Osteoporos Int 26:2249–2255

    Article  CAS  PubMed  Google Scholar 

  7. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309

    Article  CAS  PubMed  Google Scholar 

  8. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397. https://doi.org/10.1007/s00198-007-0543-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M, A-TOP (Adequate Treatment of Osteoporosis) Research Group (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)—02. Curr Med Res Opin 27:1273–1284

    Article  CAS  PubMed  Google Scholar 

  11. Nakamura T, Osawa M, Itoh M, Yamaguchi H, Iinuma N, Hayakawa Y, Suzuki H, Kamisaki T, Iwayama S, Nishikawa M (2012) The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. J Bone Miner Metab 30:715–721

    Article  CAS  PubMed  Google Scholar 

  12. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Y, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) Research Group (2014) Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture. Clin Ther 36:225–235

    Article  CAS  PubMed  Google Scholar 

  13. Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥ 33 ng/ml. Osteoporos Int 23:2479–2487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Institute of Medicine, Food and Nutrition Board (2010) Dietary reference intakes for calcium and vitamin D. National Academy Press, Washington, DC

    Google Scholar 

  15. Fujikawa A, Suzue T, Jitsunari F, Hirao T (2011) Evaluation of health-related quality of life using EQ-5D in Takamatsu, Japan. Environ Health Prev Med 16:25–35

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all investigators who participated in this study.

Author information

Authors and Affiliations

  1. School of Health Science, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan

    Hiroshi Hagino

  2. Department of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara, 630-0293, Japan

    Satoshi Soen

  3. Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan

    Toshitsugu Sugimoto

  4. Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachidori, Chuo-ku, Niigata, 951-8510, Japan

    Naoto Endo

  5. Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan

    Ryo Okazaki

  6. Department of Food and Nutrition, Kyoto Women’s University, 35 Imagumanokitahiyoshi-cho, Higashiyama-ku, Kyoto, 605-8501, Japan

    Kiyoshi Tanaka

  7. Aoba Hospital, 2-15-2 Taishido, Setagaya-ku, Tokyo, 154-0004, Japan

    Toshitaka Nakamura

Authors
  1. Hiroshi Hagino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Soen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshitsugu Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoto Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryo Okazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kiyoshi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshitaka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Hagino.

Ethics declarations

Conflict of interest

This study was funded by the Japan Association of Health Service.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hagino, H., Soen, S., Sugimoto, T. et al. Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan. J Bone Miner Metab 37, 273–281 (2019). https://doi.org/10.1007/s00774-018-0914-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-018-0914-3

Keywords

Search

Navigation